The IMBG is not meant to replace the therapeutic drug monitoring (TDM), as TDM measure pharmacokinetics of the drugs but gives no information about the pharmacodynamic effect of them in the immune system. A concomitant evaluation of pharmacodynamics and pharmacokinetics of the drugs can be an advisable tool to perform successful patient-tailored immunosuppressive therapy.

The IMBG can support clinicians in the selection of the optimal combination/posology of immunosuppressant drugs and it will be a complementary tool to TDM, which allows that a selected drug reaches in blood the therapeutic levels needed to be effective.